Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 101-120 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 101 | Orbitworks lowweak | Opp 4 Risk 2 | Thesis: The reviewed sources' membership rationale says Orbitworks is an Abu Dhabi satellite integrator planning a 50-satellite AI-powered Earth observation constellation and participating in a SAR satellite program. If accurate and current, that implies meaningful long-horizon platform and constellation buildout opportunity, but the reviewed sources lack direct supporting summaries or available evidence. Why now: The rationale references growth-oriented planned activity, which is relevant to a 1 year+ horizon, yet timing confidence is limited because coverage data shows no evidence after recent evidence window. Caveats: Membership rationale references article IDs, and: but and article summaries are not provided in the reviewed sources. No direct positive_evidence or negative_evidence arrays are populated. Opportunity is based on stated plans, not validated conversion, contracts, or operating milestones inside the recent evidence window. |
| 102 | Overview Energy lowweak | Opp 4 Risk 3 | Thesis: Reviewed evidence rationale says Overview Energy won a U.S. Air Force contract for orbit-to-grid energy technology using geosynchronous satellites and space-based solar power. A defense contract in an ambitious emerging category is positive for strategic validation over a 1 year+ horizon. Why now: The likely catalyst is the reported Air Force contract, yet the reviewed sources gives no retained article summary or evidence row to establish recency or contract scale. Caveats: Phase2 membership rationale references: but no article summary or evidence are available. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 103 | Pacific Defense lowweak | Opp 4 Risk 3 | Thesis: Reviewed evidence context says Pacific Defense launched the Moonraker payload, described as the first on-orbit demo of a reprogrammable payload for SSA/EMSO, developed under an AFRL contract. An on-orbit demo tied to a government contract is stronger business progress context than most peers in this screen and could support longer-horizon defense-space opportunity if follow-on adoption occurs. Why now: The company appears more advanced than several peers because the reviewed sources references an on-orbit demo under contract, but there is no citable recency signal beyond membership support article ID: and no available evidence after recent evidence window. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources provide no or article summary for citation. Opportunity score is relative within a weak-evidence batch, not high absolute conviction. |
| 104 | Portal Space Systems lowweak | Opp 4 Risk 3 | Thesis: Reviewed evidence rationale says Portal Space Systems raised a $50M Series A and offers commercial debris removal as a service with its Starburst spacecraft, which is directionally positive for a long-horizon growth thesis if validated. Why now: Potential why-now would be the reported Series A and service positioning, but recency cannot be verified because no evidence are retained after the recent evidence window. Caveats: Phase2 membership rationale references: but no article summary or evidence are included. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Slightly higher opportunity than some peers only because the reviewed sources rationale mentions both financing and product/service positioning. |
| 105 | QOSMIC lowweak | Opp 4 Risk 2 | Thesis: QOSMIC has some opportunity potential because reviewed sources context says it raised about $3.3 million in seed funding to build optical communications infrastructure for space, with proceeds intended for engineering expansion, manufacturing scale-up, and deployment of optical communication terminals. That indicates an early-stage capital infusion tied to product buildout, but the evidence is undated and article-level rather than direct dated event evidence. Why now: Why now is weak because the only support is undated context articles; the reviewed sources explicitly says no is available, so recency-sensitive claims should be treated cautiously for these funding and expansion statements Evidence
Caveats: Evidence is undated; recency is uncertain. Support is supporting article context only, not direct structured positive event evidence. Same funding story appears in two articles and should not be treated as independent confirmation. |
| 106 | Quantum Space lowweak | Opp 4 Risk 2 | Thesis: The reviewed sources membership rationale says Quantum Space was selected by the U.S. Space Force for the Andromeda space monitoring satellite program. If current and material, that indicates credible government-program positioning in a strategically durable market. Why now: The reviewed sources provide no post-recent evidence window detailed evidence, but the membership rationale specifically references selection for the Andromeda program via article. Because the underlying article summary/ is not included here, timing and magnitude are uncertain. Caveats: No representative article or is included for the cited Andromeda selection evidence. Selection for a program is positive, but without award size or timing the business impact is unclear. Scores are capped by missing direct article-level support. |
| 107 | Sierra Nevada Corporation mediummedium | Opp 4 Risk 2 | Thesis: Sierra Nevada Corporation has the strongest available reviewed sources signal because a within the recent evidence window article says Space Systems Command awarded more than $1.8 billion in Andromeda contracts and included Sierra Space among the awarded companies, indicating participation in a potentially durable U.S. national-security space program if the Sierra Space/Sierra Nevada linkage holds. Why now: The key surviving context is dated April 8, 2026, within the 90-day recent evidence window, and references recent contract awards under Andromeda that could matter over a 1 year+ horizon if they convert into meaningful program work. Article timestamp: April 8, 2026, basis: source date. Evidence is from at Evidence
Caveats: Evidence is supporting article context, not a direct structured positive event row for Sierra Nevada Corporation. Reviewed evidence explicitly notes entity-resolution ambiguity between Sierra Nevada Corporation and Sierra Space. The second representative article is older than the 90-day recent evidence window and should not drive recency, published September 2, 2025. |
| 108 | SpinLaunch lowweak | Opp 4 Risk 4 | Thesis: Reviewed evidence context says SpinLaunch's Meridian Space broadband constellation has 280 satellites being built. If accurate and current, that implies a tangible manufacturing/program buildout that could become strategically meaningful over a 1 year+ horizon. Why now: There is no direct, dated catalyst in the available evidence. The reviewed sources references article ID: for membership support, but provides no and shows 0 evidence after recent evidence window, so current status cannot be verified. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources does not include a or summary for citation. |
| 109 | Starcloud lowweak | Opp 4 Risk 2 | Thesis: Starcloud has the strongest relative opportunity case in this screen, albeit still low-conviction, because the reviewed sources' membership rationale references a reported $170M Series A and orbital AI/data-center activity. For a 1 year+ horizon, fundraising plus infrastructure ambition could matter if execution follows, but the reviewed sources provide no direct positive evidence, no, and no validated chronology inside the recent evidence window. Why now: If the fundraising and product positioning are recent, they could support a multi-quarter buildout story, but the reviewed sources explicitly shows zero available evidence after recent evidence window, so recency and sequencing cannot be confirmed. Caveats: Most supportive facts appear only in membership rationale, not available evidence. Reported funding cannot be treated as fully validated without direct article support in reviewed sources. No, quote, or dated direct summary is available. |
| 110 | Stelleo lowweak | Opp 4 Risk 2 | Thesis: Stelleo has some opportunity appeal because recent company-context evidence positions it as a Polish Earth Observation startup turning satellite intelligence into operational decisions for infrastructure, agriculture, and environmental users across Europe, suggesting a commercially relevant application layer. Why now: The article is within the recent evidence window and dated May 25, 2026, but it is a company-site style description rather than an independently reported business event, so it supports relevance more than momentum Evidence
Caveats: Evidence is article-level company context, not a direct commercial milestone. No direct traction, financing, or contract evidence is provided. Same-article repeated rows are not independent confirmation. |
| 111 | ThinkOrbital lowweak | Opp 4 Risk 3 | Thesis: ThinkOrbital has a speculative long-horizon opportunity signal because a dated May 2026 company-context article describes products spanning space domain awareness and in-space servicing, including ThinkX and a robotic arm/end effector. That suggests exposure to strategically important capability areas if the products convert into funded programs. Why now: Why now is the dated company-context article from May 28, 2026, recent within the recent evidence window, but it is still weak grounding because it is article-level website context rather than a confirmed business event. Evidence
Caveats: Evidence is article-level website context, not direct contract or financing evidence. Single-source evidence limits corroboration. No dated proof of revenue, customer adoption, or deployment is included. |
| 112 | Viasat, Inc. mediummedium | Opp 4 Risk 2 | Thesis: Viasat has modest opportunity support from recent supporting article context showing it was selected as a prime contractor in the U.S. Space Force Protected Tactical Satcom-Global program and that Rocket Lab will supply the spacecraft bus for Viasat's PTS-G satellite, indicating active participation in a next-generation military satcom program. Why now: Recent context exists within the recent evidence window: is dated June 11, 2026 and states Viasat was among operators selected under a combined $437.7 million award and has a defined supplier stack for its PTS-G satellite, which could matter over a 1 year+ horizon. Source date basis is source date. Evidence
Caveats: This is supporting article context only; the reviewed sources classifies it under weak context, so it is weaker than direct event/fact evidence. Same article appears in two weak-context rows and should not be treated as independent confirmation. An older Viasat company-hosted article exists but is outside recent evidence window, February 29, 2024 |
| 113 | Volta Space Technologies lowweak | Opp 4 Risk 5 | Thesis: Volta Space Technologies has an interesting long-horizon speculative opportunity because the reviewed sources rationale says it is developing a lunar laser power transmission system, with a 2028 demonstration planned and a payload booked on Firefly's Blue Ghost Mission 2. Why now: The rationale cites article and says the company has a 2028 demonstration planned with payload booked on Blue Ghost Mission 2, which is relevant to a 1 year+ strategic horizon but weak for immediate evidence-based ranking because no article body or is visible. Caveats: No visible representative article, quote, or in the reviewed sources body. The main cited demonstration is scheduled for 2028, so commercial payoff may sit beyond the stated 1 year+ ranking horizon. The Firefly payload linkage cannot be used as counterparty propagation evidence beyond the explicit rationale. |
| 114 | VyomIC lowweak | Opp 4 Risk 3 | Thesis: The membership rationale describes VyomIC as a Bengaluru-based New Space startup deploying a private global PNT satellite constellation in LEO, with first satellites planned for 2027 and 2028. That suggests large strategic upside over a 1 year+ horizon if financing and execution continue. Why now: Why now is moderate only because the business is framed around future constellation deployment and milestone timing beyond the immediate term; however, recency cannot be validated because no recent evidence window evidence are available. Caveats: Membership rationale cites article IDs and, but no are present. No representative article text or direct event/facts are available after the 90-day recent evidence window. Scoring reflects early-stage optionality and execution risk, not direct verified traction. |
| 115 | Wyvern lowweak | Opp 4 Risk 4 | Thesis: Wyvern has a plausible long-term opportunity in hyperspectral Earth observation. The reviewed sources say the company launched commercial hyperspectral satellites in 2023 and claims to be the only commercial provider with a ready-to-task constellation, which, if current, suggests existing capacity and differentiated imagery access. Why now: Why now is weak because the evidence retained is undated and the reviewed sources explicitly says to treat recency-sensitive claims cautiously when no is available. The underlying strategic area may be attractive, but current business-state confirmation is missing. Evidence
Caveats: Evidence is undated, so current-state claims are less reliable for timing judgments. Only supporting article context is provided, not direct event evidence. No direct customer, contract, financing, or negative-event evidence is shown. |
| 116 | AAC Clyde Space AB lowweak | Opp 3 Risk 3 | Thesis: Membership rationale says AAC Clyde Space signed a EUR 10.9 million ESA contract for a 12-satellite VDES constellation, which would be meaningful positive evidence for a 1 year+ horizon if directly available, but these reviewed sources provide no surviving evidence or article summaries to substantiate the current state beyond the rationale reference (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources' recent evidence review and coverage data show zero available evidence after recent evidence window despite the membership rationale referencing a material contract. Caveats: No current evidence is provided for Contract claim appears only in membership rationale, not in available direct evidence fields. No recency-confirmed follow-through evidence is available. |
| 117 | Agnikul lowweak | Opp 3 Risk 2 | Thesis: Agnikul appears to have credible long-horizon opportunity potential because the reviewed sources places it among Indian spacetech beneficiaries and identifies it as 'launch infrastructure' in one summary, suggesting sector exposure that could matter over a year-plus horizon if operating milestones follow. Why now: The only timing argument is broad strategic sector positioning in Indian spacetech; there is no validated current catalyst in available evidence. Caveats: Phase-2 rationale references: and: but the reviewed sources does not provide or summaries. Sector beneficiary framing is weaker than direct company event/fact evidence. Coverage debug shows zero evidence after recent evidence window. |
| 118 | Arctus Aerospace lowweak | Opp 3 Risk 2 | Thesis: Arctus Aerospace has a modestly better long-horizon opportunity case than most peers in this screen because the reviewed sources rationale states it raised $2.6M and is developing HALE UAVs for earth observation, indicating financing plus product development progress (: no provided in reviewed sources). Why now: Funding plus ongoing development could matter over a 1 year+ horizon, but there is no retained dated evidence row to confirm timing, financing close date, or development milestone sequence. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. The positive case relies on phase2 rationale rather than retained direct event/facts. |
| 119 | Astrolab lowweak | Opp 3 Risk 3 | Thesis: Reviewed evidence membership rationale says Astrolab received NASA moon-base/lunar-terrain-vehicle related contract support, which could be favorable over a 1 year+ horizon if active, but no available article evidence remains to support a stronger current ranking. Why now: Why-now support is weak because coverage data shows no evidence after recent evidence window, so the cited lunar contract context cannot be refreshed from available evidence. Caveats: Phase2 rationale cites, and: but no representative article or evidence are available for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Private-company watch item rather than high-conviction ranked candidate. |
| 120 | Axelspace Corporation lowweak | Opp 3 Risk 3 | Thesis: Membership rationale states Axelspace is launching seven GRUS-3 Earth observation microsatellites and expanding its constellation to more than 10 satellites, which would support an opportunity thesis tied to capacity expansion, but no direct evidence or article summaries are available in the reviewed sources after recent evidence window (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources references a potentially important constellation expansion but provides no post-recent evidence window available evidence to confirm status or timing. Caveats: No current evidence is provided for No direct evidence remained after the recent evidence filter. Recency of constellation expansion cannot be validated from reviewed sources fields. |
Risk view
Showing rows 121-140 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 121 | Aalyria Technologies mediumweak | Opp 5 Risk 2 | Thesis: The reviewed sources includes no material negative evidence; the main risk is thin grounding because the conclusion relies on one cited contract-related article without available detail or corroboration. Why now: Current relevance is tied to the cited Space Force Golden Dome contract award context in article, though the reviewed sources omits the and representative article details. Caveats: No article is supplied for the cited support article. Opportunity rests on a single contract-related rationale summary. Contract inclusion alone does not reveal contract size, economics, or conversion pace. |
| 122 | Agnikul lowweak | Opp 3 Risk 2 | Thesis: Risk is moderate because the reviewed sources explicitly says it lacks direct, specific evidence of rocket company operations or a funding/contract event for Agnikul itself in the included material, so the opportunity case is not adequately grounded. Why now: The only timing argument is broad strategic sector positioning in Indian spacetech; there is no validated current catalyst in available evidence. Caveats: Phase-2 rationale references: and: but the reviewed sources does not provide or summaries. Sector beneficiary framing is weaker than direct company event/fact evidence. Coverage debug shows zero evidence after recent evidence window. |
| 123 | Antaris Inc. lowweak | Opp 2 Risk 2 | Thesis: Current ranking risk is mostly uncertainty risk: without retained evidence inside the 90-day window, the reviewed sources does not establish whether the referenced programs are progressing, delayed, funded, or commercially material. Why now: There is no retained 90-day evidence in these reviewed sources despite references to evidence in earlier processing. Recency-sensitive conclusions therefore cannot be made from the local reviewed sources. Caveats: Membership rationale references older evidence but no article IDs are provided with accessible summaries in these reviewed sources body. No representative articles or retained evidence are included. Low score reflects evidence absence, not a negative business judgment. |
| 124 | Apogeo Space lowweak | Opp 4 Risk 2 | Thesis: No material adverse evidence is provided, but the reviewed sources does not show contract economics, execution milestones, or customer traction, so commercialization risk remains. Why now: The reviewed sources' membership rationale cites article: for the integration agreement and technical collaboration, but no article or direct evidence are included. Caveats: Evidence is thin and article-level details are missing. Collaboration and integration agreements are weaker than revenue-bearing customer wins. Single-article support limits conviction. |
| 125 | Arctus Aerospace lowweak | Opp 3 Risk 2 | Thesis: The reviewed sources also explicitly says it is unclear whether Arctus is a true space company versus an atmospheric UAV company. That category ambiguity weakens thesis durability for this specific ranking universe, and no adverse company-specific event is otherwise available. Why now: Funding plus ongoing development could matter over a 1 year+ horizon, but there is no retained dated evidence row to confirm timing, financing close date, or development milestone sequence. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. The positive case relies on phase2 rationale rather than retained direct event/facts. |
| 126 | Argotec lowweak | Opp 1 Risk 2 | Thesis: The main risk is evidentiary opacity: no kept structured positive or negative rows are available after recent evidence window, so business-state, traction, and durability are uncertain. Why now: Why now is weak because the reviewed sources show zero evidence kept within the 90-day recent evidence window for ranking, and the only cited support is an older membership rationale referring to 7 Hawk microsatellites for Italy's IRIDE constellation aboard a SpaceX launch from article: but no article or dated evidence row is provided in the reviewed sources for ranking use. Caveats: No article is provided for the membership support article: so it cannot be cited as a factual ranked-evidence item under the the evidence standard. Coverage debug shows zero evidence after recent evidence window. Private/public status is not used as a filter and is unclear from these reviewed sources. |
| 127 | Astranis lowmedium | Opp 4 Risk 2 | Thesis: The evidence is mostly supporting article context rather than strong company-specific event extraction, so execution and conversion risk remain, but there is no direct adverse evidence available. Why now: Recent dated context within the 90-day recent evidence window points to fresh financing and government program inclusion, both relevant for a 1 year+ horizon: Andromeda context on April 8, 2026 and funding context on June 19, 2026 Evidence
Caveats: Evidence is mainly supporting article context, which is weaker than direct event/fact evidence. An older 2025 article about a 2027 transportation deal exists, but it is outside the recent evidence window and not used as current proof. |
| 128 | Astranis Space Technologies lowweak | Opp 2 Risk 2 | Thesis: There is no direct adverse evidence, but the ranking is constrained by zero retained evidence after recent evidence window and potential duplication concerns in the broader article set. Why now: The current batch retains no representative articles or evidence within the 90-day recent evidence window for Astranis, so the reviewed sources does not provide a current dated catalyst despite the phase-2 rationale. Caveats: No retained evidence after recent evidence window. Phase-2 rationale mentions duplicate article versions; duplicates would not be independent confirmation anyway. |
| 129 | Astrobotic Technology lowweak | Opp 2 Risk 2 | Thesis: No material adverse evidence is available in the reviewed sources, so a negative thesis is unsupported. Why now: The rationale references articles, and: but no corresponding available evidence remains available for direct scoring after recent evidence filtering. Caveats: Lunar lander category fit does not equal thesis attractiveness. Coverage debug shows zero available evidence after recent evidence window. Without direct execution, funding, contract-conversion, or mission-status evidence, scores should remain conservative. |
| 130 | Astrolight UAB lowweak | Opp 2 Risk 2 | Thesis: The key risk is that the only described support is partner context, and the reviewed sources explicitly notes the relation row is context-only, leaving no strong basis for a company-specific positive or negative operating thesis. Why now: There is no usable 'why now' beyond possible strategic relevance to optical communications. The reviewed sources provide no after-recent evidence window evidence to confirm current status. Caveats: Phase-2 rationale references, but the reviewed sources does not include its or article summary. Relations marked context-only cannot be used as counterparty propagation evidence. Coverage debug shows zero evidence after recent evidence window. |
| 131 | Azista Industries Private Limited lowweak | Opp 3 Risk 2 | Thesis: The risk is that technical demonstration does not confirm scalable commercial adoption, contracts, or follow-on funding, and none of those are evidenced in the kept reviewed sources rows. Why now: The only support cited is article in the membership rationale. Because the company coverage report shows zero articles after recent evidence window and zero evidence after recent evidence window, there is no robust timing catalyst beyond the historical demonstration narrative. Caveats: Single-article support only, and not available as active evidence. No direct evidence on customer conversion, regulatory adoption, or funding. Private-company visibility is limited in these reviewed sources. |
| 132 | Azista Space lowweak | Opp 2 Risk 2 | Thesis: Risk is mostly uncertainty from minimal coverage: only one article was considered and zero evidence were available after recent evidence window, so durability, backlog, and execution status are unverified here. Why now: Why now is weak because there is no surviving 90-day evidence row in the reviewed sources to establish recency or momentum. Caveats: Only membership rationale is available; no citeable direct evidence with are provided. Single-article universe increases fragility of inference. |
| 133 | Beijing Guodian High-Tech Technology Co lowweak | Opp 4 Risk 2 | Thesis: No direct adverse evidence is provided in the reviewed sources; main risk is limited visibility into commercialization and scale from the single referenced article. Why now: The implied catalyst is the pilot-program approval, but the reviewed sources provide no retained article summary or timestamped evidence row beyond the membership rationale. Caveats: Phase2 membership rationale references: but the actual summary/evidence are absent. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Opportunity score is restrained because approval alone is described in rationale but not directly evidenced here. |
| 134 | Bellatrix Aerospace lowweak | Opp 3 Risk 2 | Thesis: Risk is primarily execution and verification uncertainty because the reviewed sources have zero available evidence after recent evidence window, so no current milestone, financing, or contract confirmation is available. Why now: Why now is only moderate in theory because propulsion/platform partnerships can matter over a 1-year-plus horizon, but these reviewed sources does not provide recency-anchored evidence after recent evidence window. Caveats: No direct evidence with available for citation. Technology differentiation is only inferred from membership rationale and is not independently corroborated in available evidence. |
| 135 | Blackstar Orbital lowweak | Opp 2 Risk 2 | Thesis: The main risk is evidence quality: the reviewed sources itself says the evidence is mostly partnership context and lacks direct company-specific operating detail, which weakens any durable 1 year+ thesis. There is still no material adverse event available after recent evidence window. Why now: No near-term or durable catalyst can be established from retained evidence because coverage debug shows zero article IDs and zero evidence after recent evidence window. Caveats: No are provided for the cited support articles in the reviewed sources. The reviewed sources explicitly characterizes the evidence as mostly partnership context rather than direct operating detail. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 136 | Boeing highstrong | Opp 8 Risk 2 | Thesis: Source-specific risk is low because there is no available direct adverse evidence tied to Boeing's space thesis in this screen. The main offset is that the contract contributes to a long-cycle program with delivery beginning in 2031, so near-term financial realization is likely gradual rather than immediate, but that is not a negative event Why now: Why now is strong because the contract was reported on June 23-25, 2026, making it recent within the 90-day recent evidence window, and it represents a fresh, material U.S. defense-space award with multiyear strategic relevance Evidence
Caveats: Some corroborating rows are supporting article context and should not be overcounted as independent confirmation. Program financial benefits may phase in over a long cycle given first delivery timing in 2031. |
| 137 | Brightside Group S.A. lowweak | Opp 2 Risk 2 | Thesis: Risk is modest due to lack of current corroborating evidence rather than any adverse development. The reviewed sources contain no direct negative evidence. Why now: Why now is weak because no representative article or direct evidence survives in the ranking fields after recent evidence window; only membership rationale references without surfaced article content. Caveats: No direct within the recent evidence window evidence is available in ranking fields. Membership rationale alone is weaker than surfaced company-specific event evidence. No negative thesis is supportable from the reviewed sources. |
| 138 | CAS Space lowweak | Opp 2 Risk 2 | Thesis: The same rationale says there is little direct company-specific detail beyond inclusion in that group. Without available direct evidence after recent evidence window, the main risk is thesis fragility and inability to verify the claimed IPO/pre-IPO progression. Why now: There is no verified current catalyst in retained evidence. IPO/pre-IPO framing could matter on a 1 year+ horizon, but recency and milestone state cannot be confirmed here because no dated evidence are available after recent evidence window. Caveats: No are provided for the cited support articles in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. IPO/pre-IPO mention is only in reviewed sources rationale, not in retained direct evidence. |
| 139 | Casimir Inc. lowweak | Opp 1 Risk 2 | Thesis: Casimir carries above-peer evidence risk in this screen because the sole cited support is described in the phase2 rationale as blog commentary, and the business fit to the target cohort is explicitly questioned. That weak grounding raises the risk of over-interpreting the financing mention. Why now: There is no available article summary or evidence row after recent evidence window, so the only 'why now' is the uncitable phase2 statement about a seed round referenced by article id: without. Caveats: The reviewed sources itself says the support article is blog commentary, weakening source quality. No citable or summary is provided for the referenced article id No evidence were available after recent evidence window in the served reviewed sources. |
| 140 | constellr mediummedium | Opp 5 Risk 2 | Thesis: Risk remains moderate because the evidence is still supporting article context rather than direct company disclosures about backlog, margins, or contracted demand, and no negative evidence is available. Execution risk remains around converting first-launch and funding momentum into durable commercial scale. Why now: Why now is relatively strongest here because the retained evidence is within the 90-day recent evidence window and dated April 16, 2026, summarizing recent business-state milestones including a first satellite launch in January 2025 and a Series A closed in February 2026. Evidence
Caveats: Evidence is external article context, not a direct company filing or contract announcement. |